Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytori expands partnership agreement with Green Hospital Supply
As with the commercialization agreement for Japan, revenues from all related product sales will be shared equally between Cytori and Green Hospital Supply. The StemSource cell bank is
As with the commercialization agreement for Japan, revenues from all related product sales will be shared equally between Cytori and Green Hospital Supply. The StemSource cell bank is
The product is available in bottles of 100 capsules for immediate shipment to wholesalers and pharmacies across the US. Roxane Laboratories’s Zaleplon capsules CIV are AB rated to
Under the trademark of Penzim, Zymetech owns the worldwide patents for an active ingredient called Penzyme derived from enzymes produced by fish, particularly cod in the North Atlantic.
In a placebo-controlled, double-blind, four-week Phase IIa study, INT131 administration demonstrated a significant improvement in fasting plasma glucose compared to baseline and placebo at doses of 1mg and
The six-month Phase III study will involve up to 750 patients with Type-1 diabetes mellitus in 36 centers located in the US, Canada, Russia and eastern Europe. The
Under the terms of the collaboration, Laboratory Corporation of America Holdings (LabCorp) will be Vanda’s exclusive commercialization partner for tests for genetic markers of the Fanapta program. Vanda
This research will test the efficacy of an ImmunoVaccine Technologies’s (IVT) pandemic influenza vaccine formulation delivered using Bioject’s flagship Bioject B2000 device. The research will compare the onset,
Under the terms of the agreement Jiangsu Aosaikang Pharmaceutical (ASK) will pay Access an upfront fee and subsequent milestone payments along with a double digit royalty upon commercialization
Lev has also announced plans to launch LevCare, a program designed to ensure that patients have ready access to Cinryze once it becomes commercially available in the US.
The ongoing Phase II single-arm study of GCS-100 given intravenously as a single agent to relapsed chronic lymphocytic leukemia (CLL) patients is designed to evaluate the effects of